Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

3.575 +0.305 (+9.33%)
Streaming Delayed Price Updated: 12:05 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,206,731
Open 3.360
Bid (Size) 3.570 (8)
Ask (Size) 3.580 (15)
Prev. Close 3.270
Today's Range 3.330 - 3.660
52wk Range 2.300 - 24.97
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
Although breakout stocks present high risks, the underlying lack of predictability provides fuel for tremendous upside. 
Via InvestorPlace
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire

Performance

YTD
-61.60%
-61.60%
1 Month
+21.60%
+21.60%
3 Month
-19.48%
-19.48%
6 Month
-43.34%
-43.34%
1 Year
-84.69%
-84.69%

More News

Read More
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Via InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
Via InvestorPlace
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Via Benzinga
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire
GDS Holdings, Coinbase And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces Proposed Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.